Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
Ticker SymbolDERM
Company nameJourney Medical Corp
IPO dateNov 12, 2021
CEOMr. Claude Maraoui
Number of employees41
Security typeOrdinary Share
Fiscal year-endNov 12
Address9237 E Via De Ventura Blvd., Suite 105
CitySCOTTSDALE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code85258
Phone14804346670
Websitehttps://journeymedicalcorp.com/
Ticker SymbolDERM
IPO dateNov 12, 2021
CEOMr. Claude Maraoui
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data